Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer - PubMed (original) (raw)
Review
. 2003 Sep 1;21(17):3357-65.
doi: 10.1200/JCO.2003.04.576. Epub 2003 Jul 7.
Affiliations
- PMID: 12847142
- DOI: 10.1200/JCO.2003.04.576
Review
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer
Aron Goldhirsch et al. J Clin Oncol. 2003.
Abstract
This account of the highlights of the eighth St Gallen (Switzerland) meeting in 2003 emphasizes new information that has emerged during the 2 years since the seventh meeting in 2001. This article should be read in conjunction with the report of that earlier meeting. Recommendations for patient care are so critically dependent on assessment of endocrine responsiveness that the importance of high-quality steroid hormone receptor determination and standardized quantitative reporting cannot be overemphasized. The International Consensus Panel modified the risk categories so that only endocrine receptor-absent status was sufficient to reclassify an otherwise low-risk, node-negative disease into the category of average risk. Absence of steroid hormone receptors also was recognized as indicating endocrine nonresponsiveness. Some important areas highlighted at the recent meeting include: (1) recognition of the separate nature of endocrine-nonresponsive breast cancer-both invasive cancers and ductal carcinoma-in-situ; (2) improved understanding of the mechanisms of acquired endocrine resistance, which offer exciting prospects for extending the impact of successful sequential endocrine therapies; (3) presentation of high-quality evidence indicating that chemotherapy and tamoxifen should be used sequentially rather than concurrently; (4) availability of a potential alternative to tamoxifen for treatment of postmenopausal women with endocrine-responsive disease; and (5) the promise of newly defined prognostic and predictive markers.
Similar articles
- Comments on the St. Gallen Consensus 2003 on the Primary Therapy of Early Breast Cancer.
Senn HJ, Thürlimann B, Goldhirsch A, Wood WC, Gelber RD, Coates AS. Senn HJ, et al. Breast. 2003 Dec;12(6):569-82. doi: 10.1016/j.breast.2003.09.007. Breast. 2003. PMID: 14659136 Review. - Meeting highlights--International Consensus Panel on the treatment of primary breast cancer.
Taguchi T. Taguchi T. Gan To Kagaku Ryoho. 2002 Mar;29(3):347-63. Gan To Kagaku Ryoho. 2002. PMID: 11915723 Review. - Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.
Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ; Panel members. Goldhirsch A, et al. Ann Oncol. 2005 Oct;16(10):1569-83. doi: 10.1093/annonc/mdi326. Epub 2005 Sep 7. Ann Oncol. 2005. PMID: 16148022 - Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.
Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thürlimann B, Senn HJ; 10th St. Gallen conference. Goldhirsch A, et al. Ann Oncol. 2007 Jul;18(7):1133-44. doi: 10.1093/annonc/mdm271. Ann Oncol. 2007. PMID: 17675394 Review.
Cited by
- Pseudo-value regression trees.
Schenk A, Berger M, Schmid M. Schenk A, et al. Lifetime Data Anal. 2024 Apr;30(2):439-471. doi: 10.1007/s10985-024-09618-x. Epub 2024 Feb 25. Lifetime Data Anal. 2024. PMID: 38403840 Free PMC article. - Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare.
Müller V, Fasching PA, Nabieva N, Fehm TN, Thill M, Schmidt M, Kühn T, Banys-Paluchowski M, Belleville E, Juhasz-Böss I, Untch M, Kolberg HC, Harbeck N, Aktas B, Stickeler E, Kreuzeder J, Hartkopf AD, Janni W, Ditsch N. Müller V, et al. Geburtshilfe Frauenheilkd. 2023 May 23;83(6):673-685. doi: 10.1055/a-2073-1887. eCollection 2023 Jun. Geburtshilfe Frauenheilkd. 2023. PMID: 37614683 Free PMC article. - Does Apoptotic Index Predict the Response to Neoadjuvant Chemotherapy in Patients with Breast Carcinoma?
Askan G, Okcu O, Ozturk C, Duman Ozturk S, Sen B, Bedir R. Askan G, et al. Medeni Med J. 2023 Mar 28;38(1):1-7. doi: 10.4274/MMJ.galenos.2022.59196. Medeni Med J. 2023. PMID: 36974369 Free PMC article. - The complex nature of heterogeneity and its roles in breast cancer biology and therapeutic responsiveness.
Andrade de Oliveira K, Sengupta S, Yadav AK, Clarke R. Andrade de Oliveira K, et al. Front Endocrinol (Lausanne). 2023 Feb 23;14:1083048. doi: 10.3389/fendo.2023.1083048. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 36909339 Free PMC article. Review. - Adjuvant Docetaxel in Node-Negative Breast Cancer Patients: A Randomized Trial of AGO-Breast Study Group, German Breast Group, and EORTC-Pathobiology Group.
Thomssen C, Vetter M, Kantelhardt EJ, Meisner C, Schmidt M, Martin PM, Clatot F, Augustin D, Hanf V, Paepke D, Meinerz W, Hoffmann G, Wiest W, Sweep FCGJ, Schmitt M, Jänicke F, Loibl S, Minckwitz GV, Harbeck N; NNBC 3-Europe Study Group. Thomssen C, et al. Cancers (Basel). 2023 Mar 3;15(5):1580. doi: 10.3390/cancers15051580. Cancers (Basel). 2023. PMID: 36900372 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical